InnoCare Pharma Limited
9969
2024 6 30
2024 6 30
2023 6 30
–1–
6 30
2024 2023
419,738 377,549
(60,140) (76,072)
359,598 301,477
111,356 131,265
(157,153) (191,208)
(420,822) (358,130)
(91,511) (87,299)
(33,059) (179,150)
(267,952) (429,184)
(242,992) (206,261)
2024 2023
6 30 12 31
* 7,992,222 8,287,136
2023 6 30 320.7
30.0% 2024 6 30 417.0 MZL
2024 2023
48.8% 2023 6 30 377.5
11.2% 2024 6 30 419.7
2023
2023 6 30 301.5 19.3%
2024 6 30 359.6 2024 6 30
85.7% 2023 6 30 79.9% 5.8
*
–2–
2023 6
30 636.6 5.2% 2024 6 30
669.5 (i)
2023 6 30 191.2 34.0
2024 6 30 157.2
(ii) 62.7 2024 6
30 420.8
(iii) 2023 6 30
87.3 4.8% 2024 6 30
91.5
2023 6 30 429.2 37.6%
2024 6 30 268.0
2024 6 30 79.9
–3–
6 30
2024 2023
(267,952) (429,184)
25,308 178,005
(348) 44,918
(242,992) (206,261)
–4–
2024 13
2 30
(R&D)
ICP-248 ICP-B02 ICP-490 ICP-B05
NHL MM
2024
BTK 2024 6 30
417.0 2023 320.7
30.0%
1)
CLL/SLL
MCL
MZL
NRDL
–5–
2) MZL BTK
MZL B NHL
2023 DOI:10.1002/ajh.27058
2024 CSCO
MZL
3)
4)
DOT
2024
MZL NDA 2023 4
NMPA MZL BTK
IRC ORR 58.9%
12 PFS OS 82.8%
91%
–6–
MCL II
FDA FDA NDA
MCD B DLBCL
1L III
R-CHOP R-CHOP
MCD DLBCL 44
ICP-B04 CD19 (Minjuvi )
2024 6 BLA
CDE ASCT
DLBCL DLBCL 2025
BLA 2022
BLA ASCT
DLBCL
DLBCL
ASCT DLBCL
DLBCL
CSCO ASCT
DLBCL
–7–
ICP-248
ICP-248 B 2 BCL-2
II/III ICP-248
1L CLL/SLL 2024 5
40 ICP-248 I
CLL/SLL MCL NHL
BCL-2 PK
47 28 100mg 25 125mg 3
QD BTKi
BTKi NHL ORR 71.4% 78.5% BTK
BTKi MCL ORR 71.4% IND
2024 1
AML IND CDE
ICP-B02 (CM355)
ICP-B02 CD20 CD3 I/II
ICP-B02 NHL PK
IV SC
IV SC ICP-B02
FL DLBCL 15 ICP-B02 ≥6
ORR 100% SC 11 ORR
100.0%(11/11) CRR 63.6%(7/11) 2 DLBCL
CR CR
ICP-B02 ICP-B02
NHL IND
ICP-490
ICP-490
MM NHL I
ICP-490
–8–
PD Aiolos (IKZF3) Ikaro (IKZF1)
2023 9 IND CDE ICP-490
ICP-490 MM NHL
ICP-B05 (CM369)
ICP-B05 CC 8 CCR8
(2162.HK)
I ICP-B05 NHL
ICP-B05
150 NHL ICP-B05
DLT 3 AE
T
NHL 2024 8 1 6
6 3 (50%)
(PR)
ICP-B05
B T
3.7%
2029 1,850
2023
10 3 iHealthcareAnalyst, Inc. B T
ITP
PoC III 2023 10
–9–
2024 2025 2023 6
12 ITP II PoC EHA 2023
2024 4 (The American Journal of
Hematology) 50 QD 40%
50 QD GC
IVIG 75% 6/8 BTK ITP
SLE IIa
SLE SRI -4
IIb
CDE
MS II 24
12
Cmax 12
50 QD 80 QD 24 Gd+T1
92.3% MS
4
T1 24 80 QD Gd+ T1
24
TEAE MS
ICP-332
ICP-332 2 TYK2
T 2023 12 ICP-332
TYK-2 AD
II ICP-
332 4 AD
EASI
80 78.2%
– 10 –
120 72.5% 16.7%
(p<0.0001) ICP-332 80 120
EASI 50 EASI 75 EASI 90 EASI
50% 75% 90% (IGA) 0/1
EASI 75 80 120 64%/64%
EASI 75 8%(p<0.0001) TRAE
AD III
ICP-332
2024 AD III
ICP-332 IND 2024 6 FDA
ICP-488
ICP-488 TYK2 TYK2
JH2 IL-23 IL12 I IFN
ICP-488
ICP-488 I
PK ICP-488
1 36 ICP-488
3-12 ICP-488 <1.5
ICP-488
4 ICP-488
6 PASI
37.5% 13.8% p=0.0870 alpha 0.1 PASI
50 (0%) ICP-488 6 QD 42%
TEAE TRAE ICP-488
TEAE TRAE ICP-488
II
II 2024 5
2024
– 11 –
ICP-B02 (CM355)
ICP-B02 CD20 CD3 T T
B ICP-B02 SC IV NHL I/II
B B
ICP-B02
IL-17
IL-17
IL-17A IL-17A
IL-17AA IL-17AF IL-17R
ICP-723
ICP-189 ICP-B05
ICP-723 (Zurletrectinib)
NTRK
12 ICP-723 II
80–90% ORR Zurletrectinib TRK
TRKi
2 12 IND 2023 7 CDE
2025 NDA
– 12 –
ICP-189
ICP-189 SHP2
Ia
ICP-189
120 QD
DLT AE 3 160 QD ICP-
189 120
ICP-189 DUSP6 IC90 90%
DUSP6 MAPK ICP-189
20 1 PR 14
ICP-189 ArriVent EGFR
NSCLC I
2024 3 80 ICP-189 80
DLT 120 ICP-189 80
DUSP6 ICP-189
MAPK
ICP-192 (Gunagratinib)
Gunagratinib
FGFR I
CCA
II 2023 1 2023 ASCO-GI
gunagratinib IIa
– 13 –
2024 2.0
MZL
2023
30.0%
2024
2024
1.0
2.0
– 14 –
ICP-248 ICP-B02 ICP-490 ICP-B05
NHL
2024 6 CDE ASCT
DLBCL BLA 2025 BLA
ICP-248 1L CLL/SLL
ICP-248 AML IND CDE
B T
B
ITP II PoC III
SLE IIa SLE
BTK IIb
NMOSD II
CSU HS
T
ICP-332 AD II PoC ICP-488 PoC
T SLE LN IBD
B ICP-332 ICP-488 IL-17
T
– 15 –
ICP-723
ICP-189 ICP-B05
IND
– 16 –
IND NDA
Ia Ib II * II ** III
r/r CLL/SLL 2020 12 25
r/r MCL 2020 12 25
2023 4 21
2024
r/r MZL
r/r MCL 2024
ICP-022/ 1L: CLL/SLL 2024
BTK
1L: MCL
MZL
1L: MCD DLBCL
1L CLL/SLL ICP-248
ICP-B04/
CD19 Tafa + LEN, r/r DLBCL BLA 6 2024
ICP-B02 CD3 x CD20 IV&SC
NHL
ICP-248 BCL2
AML IND
ICP-490 E3 MM / DLBCL /
ICP-B05 CCR8
NDA
Ia Ib II * II ** III
SLE
MS
ICP-022/
BTK
ITP
NMOSD
ICP-332 TYK2 – JH1
ICP-488 TYK2 – JH2
ICP-723/
pan-TRK NTRK
Zurletrectinib
ICP-192/
Gunagratinib pan-FGFR
ICP-189 SHP2
+EGFRi
ICP-B05 CCR8
NDA
– 17 –
BTK
BTK 2022
CLL/SLL MCL 2024
MZL 2023
CLL/SLL MCL MZL CSCO BTK
DLBCL pCNSL
2024 6 30 417.0
2023 6 30 30.0% 2024
2023 48.8% 330
(i)
(ii)
MZL BTK (iii) (iv)
DOT
– 18 –
ICP-248 ICP-B02 ICP-490 ICP-B05
NHL MM
NHL MM (i)
(ii) FDA EMA
CD19 DLBCL (iii)
BCL-2 CD20 CD3 E3 CCR8
(iv)
1,300
(CLL)
(SLL) (r/r CLL/SLL)
(MCL) (r/r MCL) NMPA
(MZL) (r/r MZL)
MZL BTK
– 19 –
MZL
MZL B NHL 8%
10% MZL
MZL
2023 4 NMPA MZL
MZL BTK
2023 6 16 ICML
MZL
IRC
2014 ORR
IV 75.9%
24.3 IRC ORR 58.9% DOR 34.3
PFS 12 PFS 82.8% OS 91%
TRAE 1 2
III
(R2) R2 MZL
ASH 2023 (Jiadai Xu, Lu-Ya Cheng, Yang Ke, et al. Blood 2023
142 (Supplement 1) 6146.) MZL
MZL 10
3 (30%) CR 6 (60%) PR ORR 90% 13.0
7.8 24.7 mPFS 6 PFS
100% OS 2023 5 6 8
9.6 3.0 17.8
ORR 75% (6/8) 1 SD 1
PD
– 20 –
CLL/SLL
II CLL/SLL
150 80
CLL/SLL 2023 6 26 52.4
42.5% ORR 93.8% CR 30%
1.84 DOR PFS 52 50
CLL/SLL
BTK CR
AE
MCL
MCL B B
MCL 60
MCL
CR
2023 5 2 Blood Blood Advances
MCL
MCL
106 2023 6 9 46.98
CT ORR 83%
35.8% CR 3.8% CRu 43.4% PR
DOR 25.79 PFS 24.94 OS 56.21
MCL II
FDA NDA FDA BTD
MCL
– 21 –
(OLR)
MCL II (Huilai Zhang,Liping Su,
Lihong Liu, et al. Blood 2023 142 (Supplement 1) 736.) 21 (75.0%)
6 16 (76.2%) CR 5 (23.8%)
PR 100% 21 18
MRD 18 MRD PB-MRD MRD
BMMRD DOR mPFS 12 DOR PFS
90.9% 92.3%
1L CLL/SLL
III
CLL/SLL IRC PFS
54 III 1L CLL
1L DLBCL-MCD
DLBCL NHL 100
MCD 1L DLBCL
III R-CHOP
R-CHOP MCD DLBCL
44
40% DLBCL
R-CHOP+X
MCD B
NF-KB BTK
T ITK CD20
NK ADCC
R-CHOP MCD DLBCL
– 22 –
2022 6 ASCO
R-CHOP MCD DLBCL 14 MCD DLBCL
150 8 R-CHOP
R-EPOCH 6 RICE R-CHOP R2
CRR 75% 66.67%
MCD DLBCL
MCD DLBCL
pCNSL
EHA 2023
pCNSL II
pCNSL ND pCNSL
ORR
pCNSL
pCNSL
2022
ND pCNSL CNSL
ND pCNSL ORR 88.9% 100% CR 53.9% 61.8%
ND pCNSL
CR mPFS 6 PFS
63.6% 100%
60% CNSL ORR 60%
86.7% CR mPFS 9.8 3
mPFS
– 23 –
BCR MYD88
MOA
BBB BBB
150 21.6
BBB 58.6%
pCNSL
ICP-248 BCL-2
BTK B CLL/SLL
MCL CLL
CLL
BTK PFS
BTK OS BTK
uMRD
BCL-2 BCL-2 B
BCL-2 BTK CLL/SLL MCL
CLL/SLL
ICP-248 BCL-2 CLL/SLL
MCL
– 24 –
ICP-B04 ( )
II
ASCT DLBCL BLA 2024 6 NMPA CDE
2025
II
DLBCL
IRC ORR DCR DOR PFS TTP
TTR OS EHA 2024 2024
1 29 IRC ORR 73.1% 32.7% CR 40.4%
PR ORR 69.2% 34.6% CR 34.6%
PR
ASCT DLBCL
DLBCL DLBCL
B-NHL CD19
B-NHL
CSCO
ASCT DLBCL
BLA
ASCT DLBCL
– 25 –
DLBCL
30
ICP-248
ICP-248 B 2 BCL-2
BCL-2
BCL-2
ICP-248 ICP-248
DDI BLC2
ICP-248 BCL-2
ICP-248 CLL/SLL
NHL
ICP-248 I
I ICP-248 B
CLL/SLL MCL NHL
BCL-2 ICP-248
47
28 100mg 25 125mg 3 QD
BTKi BTKi NHL ORR 71.4% 78.5%
BTKi MCL ORR 71.4%
ICP-248 2024 1 FDA
IND 2024 1
AML IND CDE
BCL-2 BTK II/III ICP-
248 1L CLL/SLL 2024 5
40
– 26 –
ICP-B02 (CM355)
ICP-B02
B CD20 CD3
TDCC
ICP-B02 IV
SC IV SC
FL DLBCL 15
ICP-B02 ≥6 ORR 100% SC 11
ORR 100.0% (11/11) CRR 63.6% (7/11) 2 DLBCL
CR
ICP-B02 NHL
IND 2024 6 CDE
0.5/1.5/6
ICP-B02 B ICP-B02 SC
IV NHL I/II B
CR CD19
CD20 B B B
ICP-B02
ICP-490
ICP-490 Cereblon CRBN E3
IMiD TPD
– 27 –
CRL4CRBN E3 ICP-490 IKZF1
Ikaros IKZF3 Aiolos
ICP-490 MM DLBCL
ICP-490 CRBN
ICP-490 ADCC CD38
daratumumab
2023 4 18 2023 AACR ICP-490
ICP-490 MM NHL DLBCL
IC50 ICP-490
ICP-490
ICP-490 MM
DLBCL
ICP-490
ICP-490 IL-2 B CD38 daratumumab MM NHL
ICP-490 BTK
MM I ICP-490
MR
ICP-490 PD
Aiolos (IKZF3) Ikaro (IKZF1) 2023 9 IND CDE
ICP-490 ICP-490
MM
ICP-B05 (CM369)
ICP-B05 C-C 8 CCR8
CCR8 TME T
Tregs ICP-B05 CCR8 Tregs ADCC
Tregs TME
ICP-B05
– 28 –
Tregs Tregs
Tregs ICP-B05
I ICP-B05
NHL ICP-B05
150 NHL ICP-B05
DLT 3 TRAE PK
T NHL 2024 8
1 6 6
3 (50%) (PR)
ICP-B05
B T
B T
AD
T
ICP-332 (TYK2i-JH1)
ICP-488 (TYK2i-JH2) LN
IL-17i IBD
SLE
B ITP
MS
(BTKi) NMOSD
CSU
AD: SLE: NMOSD:
LN: ITP: CSU:
IBD: MS:
– 29 –
CNS
B
ITP PoC GC/IVIG
2023 III
SLE IIa SLE
BTK IIb
II NMOSD CSU HS
T
TYK2 ICP-332 ICP-488
T AD SLE
LN CD UC
B ICP-332 ICP-488 T
B —
BTK TEC B
BCR B
BTK
BTK
ITP
ITP
ITP
T
– 30 –
ITP 100,000 23.6 100,000 9.5
CD20
BTK B ITP B
BTK
ITP
ITP
2023 ITP II
II
ITP III
50 10 /L
9
2 7 4 2023 2
6 33 50 QD 30 QD
ITP 50 QD
– 31 –
GC/IVIG 36.4% 33
12 50 40% 15 6
12 83.3% 12 10
14 24 6 4 50x109/L
22 GC IVIG 50 75.0% 8
6 ITP
TRAE 1 2
II ITP
BTK ITP
BTK
2023 6 12 EHA 2023 ITP II
2024 4 (The American Journal of Hematology)
ITP PoC 2023
10 2024 2025
SLE
BTK BCR
B SLE
SLE
2025 SLE 1.06 2020 2025
0.7% 2030 SLE 1.09 2025
2030 0.5%
SLE IIa
SLE
1 1 1 1 12
50 80 100
– 32 –
IIa
50 80 100 12 SRI-4
35.7% 50.0% 61.5% 64.3%
G C3 C4 IIa
2022 EULAR
SRI-4 12
N=55
50 80 100
IIa IIb 40
IIb
SLE
SLE
SLE 1 1
1 50 75 48
SRI-4
C3 C4 dsNDA
48 50% CDE
IIa SLE BTK
SLE
– 33 –
MS
II
RRMS
MS II 24 12
Cmax
4 T1
24 12 50 QD
80 QD Gd+ T1 24 92.3%
MS
24 Gd+ T1
PHS , N=115
50 QD
50 QD
50 QD
50 BID
80 QD
QD= BID= CI= Gd+ =
4 24 (95% CI) 6.45 (3.62, 11.52) 2.10 (0.62, 7.11) 1.08 (0.30, 3.81) 0.50 (0.09, 2.74)
67.4 (-22.0, 91.3) 83.3 (33.2, 95.8) 92.3 (56.5, 98.6)
0.0958 0.0114 0.0037
80 QD Gd+T1 24
TEAE MS
ALT/AST>8xULN 50 BID
– 34 –
50 QD 80 QD
FDA
2023 2 15
5
2023 2 15
B
MS
SPMS PPMS
II MS OLE
MS BTK
NMOSD
NMOSD
45-65 0.445/100,000
4.71 1
BTK B B
BTK
BTK BTK
NMOSD
– 35 –
IIT II
T — TYK2
ICP-332
ICP-332 TYK2
TYK2 JAK IL-12/IL-23
IFN
T 17 TH17 TH1 B
AD ICP-332
TYK2 400 JAK2 JAK
TYK2 ICP-332
IBD
Pharma
Intelligence 12
0.96-22.6% 1.2-17.1% 2030
100 Frost & Sullivan AD 2019 65.7
2030 81.7 1.7%
J Allergy Clin Immunol Pract. 2021 Apr 9(4) 1488–1500
AD 33% 90%
AD
ICP-332
– 36 –
2023 12 II PoC II
ICP-332
75 AD
80mg QD 120mg QD 25
28
ICP-332 4 AD ICP-332
80 120 EASI
EASI 50 EASI 75 EASI 90 EASI ≥50% 75%
90% IGA 0/1
4 — (FAS) (FAS) 4 EASI 50 EASI 75
ICP-332 80 ICP-332 120
*p<0.0001
*p<0.0001 p<0.0001
0% 90% 88%*
-10% 80%
72%*
-16.7% 70%
-20% 64%* 64%*
(+/- SE)
60%
(EASI)
-30%
50%
(%)
-40%
40%
-50%
30%
-60% 20%
20%
-70% ICP-332 80 10% 8%
-72.5% *
ICP-332 120
-80% -78.2% * 0%
EASI 50 EASI 75
ICP-332 ICP-332
80 QD 120 QD
(DLQI)
p<0.01
ICP-332 80 ICP-332 120
(N=25) (N=25) (N=25)
D8/W1 -3.3(-4.8,-1.9) -6.5(-8.0,-5.1) -6.8(-8.4,-5.3)
p 0.0027 0.0018
D15/W2 -2.2(-4.2,-0.2) -8.7(-10.7,-6.7) -7.9(-9.9,-5.9)
p <0.0001 0.0002
D29/W4 -1.2(-3.3,0.9) -10.8(-12.8,-8.8) -8.9(-11.0,-6.8)
ICP-332 80
ICP-332 120 p <0.0001 <0.0001
– 37 –
80 120 EASI
78.2% 72.5% 16.7%
(p<0.0001) 80 120 EASI 75 64% 64%
EASI 75 8% p<0.0001 80
EASI 75 56% EASI 90 40% IGA 0/1 32% NRS≥4
56% p<0.01
(NRS) (p<0.01)
80 120 ICP-332 2
p<0.01
ICP-332 AD TRAE
TRAE TRAE
II 2024 AAD
ICP-332 II AD
AD ICP-332
III 2024
AD III ICP-332
IND 2024 6 FDA
ICP-488
ICP-488 TYK2 JH2 JH2 TYK2
JH2 TYK2 ICP-488
TYK2 TYK2 JH2
IL-23 IL-12 1 IFN
ICP-488 SLE LN IBD
ICP-488 ICP-332 TYK2
– 38 –
T
23(IL-23) T 17(Th17)
2022
1.25 2% 3%
ICP-488 I
I ICP-488
1 36 3 12
ICP-488
PK
SAD PK MAD PK
SAD 6 QD Cav IC50 TYK2
7.2-11.2
ICP-488 I SAD ICP-488 I MAD
10 3 1 (N=6) 10 3
3 (N=6)
3 QD (N=6)
(+SD) (ng/mL)
(+SD) (ng/mL)
6 (N=6)
10 2 12 (N=6) 10 2 6 QD (N=6)
24 (N=7) 12 QD (N=6)
36 (N=6)
10 1 10 1
10 0 10 0
10 -1 10 -1
0 12 24 36 48 60 72 0 12 24 36 48 60 72
– 39 –
ICP-488 1 36 ICP-488
3-12 ICP-488 <1.5
ICP-488
40% 38% 50%
42% 40%
40%
30%
30%
20%
14% 20%
10%
10%
0% 0%
ICP-488 6 QD ICP-488 6 QD TAK-279 30 QD
N=7 N=12 (5/12) (2/5)
1 Nimbus 2022 -05-19 SDI NDI-034858 Phase Ib Results Poster.pdf
4 ICP-488 6 PASI
37.5% 13.8% p=0.0870 alpha 0.1 PASI 50
(0%) ICP-488 6 QD 42% TEAE
TRAE ICP-488
ICP-488 PK II
ICP-488 II 2024 5
2024
– 40 –
ICP-723
ICP-189
NSCLC
ICP-B05
ICP-723 (Zurletrectinib)
ICP-723 TRK
TRK TRK
NTRK TRK TRK
ICP-723 TRKA/B/C TRKA G595R
G667C ICP-723 TRK
2024 7 (British Journal of Cancer)
(Nature) zurletrectinib zurletrectinib
TRK
zurletrectinib TRKA TRKB
TRKC TRKA G595R TRKA G667C
Zurletrectinib selitrectinib
repotrectinib TRKA G598R/G670A
zurletrectinib(15 mg/kg)
– 41 –
NTRK TRK
selitrectinib repotrectinib zurletrectinib 41.5 66.5 104 P < 0.05
repotrectinib(15 mg/kg) selitrectinib(30 mg/kg) P=0.0384
0.0022
TRK TRKA TRKB TRKC
NTRK1 NTRK2 NTRK3 TRK
NTRK NTRK
NTRK
NTRK
12 18 ICP-723 CDE
2023 7 2 12 IND
NTRK
12 ICP-723 II
ICP-723 NDA 2025 NDA
80%-90% Zurletrectinib TRK
TRKi
ICP-189
ICP-189 SHP2
ICP-189
SHP2 RAS-MAPK
PD-1
SHP2
– 42 –
ICP-189
ICP-189
EGFR KRAS MEK PD-1
ICP-189 ICP-189 p-ERK
DUSP6 mRNA
Ia ICP-189
120 QD DLT 3 TRAE 160 QD
ICP-189
120 ICP-189 DUSP6
IC90 DUSP6 MAPK ICP-189
20 1 PR 14
2024 Ia
ICP-189 Ib EGFR
PD-1 2023 7 14
ArriVent Biopharma ArriVent
SHP2 ICP-189 ArriVent
EGFR NSCLC
ICP-189 EGFR
ICP-189 EGFRi Ib 2024 3
80 ICP-189 80
DLT 120 ICP-189 80
DUSP6 ICP-189 MAPK
ICP-189
– 43 –
ICP-192 (Gunagratinib)
Gunagratinib
FGFR FGFR
7.1%
Gunagratinib FGFR
FGFR gunagratinib FGFR
2023 1 gunagratinib CCA IIa
ICP-192 18 CCA 17
5.57 ORR 52.9% 17 9 DCR
94.1% 17 16 mPFS 6.93 95% CI 5.42 —
TRAE
FGFR gunagratinib
CCA FGR2
(52.9%) 2023 II
50,000
GMP
NMPA BTK
2022
8
– 44 –
2023
2025
30,000
CMC
70,381
2024 4 26 2023 2023 ESG
ESG
2023 ESG 2028
2023 10%
100%
19 2024 6 30
– 45 –
6 30
2024 2023
% %
417,820 99.5 321,466 85.1
1,918 0.5 56,083 14.9
419,738 100.0 377,549 100.0
2023 6 30 377.5 2024 6
30 419.7 2023 6 30
321.5 30.0% 2024 6 30
417.8 2024 2023
48.8% 2023
6 30
2024 2023
% %
358,443 99.7 279,333 92.7
1,155 0.3 22,144 7.3
359,598 100.0 301,477 100.0
2023 6 30 301.5 19.3% 2024
6 30 359.6 2024 6 30
85.7% 2023 6 30 79.9% 5.8
– 46 –
2023 6 30 131.3
2024 6 30 111.4
2023 6 30 29.2 17.7 2024
6 30 11.5 2023 6
30 8.3 7.3 2024 6 30
1.0
2023 6 30 191.2
2024 6 30 157.2
6 30
2024 2023
% %
82,029 52.2 85,638 44.8
93,087 59.2 81,281 42.5
(31,589) (20.1) 10,542 5.5
13,626 8.7 13,747 7.2
157,153 100.0 191,208 100.0
– 47 –
2023 6 30 358.1 2024
6 30 420.8
6 30
2024 2023
% %
162,338 38.6 146,561 40.9
143,870 34.2 117,654 32.9
18,329 4.4 20,808 5.8
37,404 8.9 28,206 7.9
58,881 13.9 44,901 12.5
420,822 100.0 358,130 100.0
(i) 146.6 15.7
162.3
(ii) 117.7 26.2 143.9
(iii) 20.8 2.5 18.3
(iv) 28.2 9.2 37.4
(v) 44.9
14.0 58.9
– 48 –
2023 6 30 87.3 4.8%
2024 6 30 91.5
6 30
2024 2023
% %
41,676 45.5 39,772 45.6
12,913 14.1 13,568 15.5
9,806 10.7 11,351 13.0
8,166 8.9 7,117 8.2
6,641 7.3 4,226 4.8
12,309 13.5 11,265 12.9
91,511 100.0 87,299 100.0
2023 6 30 179.2 2024
6 30 33.1
2024 6 30 1.5
2023 6 30 2.1
2023 6 30 20.3 2024
6 30 10.5 2023 6 30
11.5 2023
2024 6 30
– 49 –
2024 2023
6 30 12 31
280,677 307,638
124,881 113,994
118,381 119,095
642,941 —
6,903,693 8,224,596
8,070,573 8,765,323
5,000 5,000
117,242 134,905
669,052 667,717
11,274 12,008
34,183 23,233
1,274,794 1,251,131
2,111,545 2,093,994
5,959,028 6,671,329
2024 6 30 5,959.0
6,903.7
280.7 124.9
118.4 642.9
117.2 669.1
1,274.8
– 50 –
2024 2023
6 30 12 31
268,816 248,942
11,861 58,696
280,677 307,638
2021
2023 12 31 114.0
2024 6 30 124.9 (i)
2023 12 31 39.0 25.4 2024 6
30 64.4 (ii) 2023 12 31 10.4
4.2 2024 6 30 14.6 (iii)
2023 12 31 62.5 17.9
2024 6 30 44.6
– 51 –
2024 2023
6 30 12 31
64,353 39,044
44,572 62,540
14,633 10,390
1,323 2,020
124,881 113,994
2023 12 31
119.1 2024 6 30 118.4
2024 2023
6 30 12 31
693,551 —
350,406 —
1,043,957 —
642,941 —
401,016 —
1,043,957 —
2024 6 30
642.9 401.0 2023 12 31
– 52 –
2024 2023
6 30 12 31
102,521 124,207
14,686 10,432
16 199
19 67
117,242 134,905
2023 12 31 667.7
2024 6 30 669.1
2024 2023
6 30 12 31
57,793 58,190
45,781 52,999
27,449 15,253
14,744 11,853
23,766 38,336
476,336 476,336
23,183 14,750
669,052 667,717
– 53 –
2024 2023
6 30 12 31
5,000 5,000
34,183 23,233
476,336 476,336
1,274,794 1,251,131
33,900 26,300
39,781 43,647
294,048 305,577
2,158,042 2,131,224
2023 12 31 2,131.2 2024 6 30
2,158.0
2023 12 31
280.9 2024 6 30 269.6
2023 12 31 759.8 2024
6 30 805.2
– 54 –
2023 12 31 293.8 2024 6 30
296.5
2023 12 31 39.0 2024 6
30 36.5
2023 12 31 5.7 2024
6 30 4.1
2023 12 31 52.4 2024 6
30 59.0
2024 2023
6 30 12 31
3.8 4.2
– 55 –
2020 3 23 8.95
250,324,000 0.000002 3,883
2,240.4
2020 3 23
H.10
2020 4 15
37,548,000
15%
322.59
2021 2 10
210,508,000 14.45
2021 2 3 2021 2 10
2022 9 21 264,648,217 0.000002
11.03
2,778.82
2024 6 30 7,992.2
2023 12 31 8,287.1
– 56 –
14.07 5%
2024 6 30
2024 6 30
2024 6 30
100% 21.5% 2023 12 31
20.8%
2024 6 30 1,274.8
294.0
38.9 476.3
155.2
76.9 2023 5
400.0 2024 6 30 43.9
356.1
– 57 –
2024 6 30
2024 6 30
2024 6 30
2015 11 3
2020 3 23 2022 9 21
– 58 –
2024 6 27 2023
2024 6 27
2024 4 27
13.51B(1)
2023
2024 4 27
2
C.2.1
(i)
(ii)
(iii)
– 59 –
C3
– 60 –
2023 9 8 200
2,198,000 11,301,210 2024 6 30
548,000 2024 2 7
2024 1 548,000 6 5.6 3,162,780
2024 2 1,650,000 5.13 4.54 8,138,430
2,198,000 11,301,210
(1)
(2) (3)
2024 4 2024 6
6,177,000 4.44
5.22 29,700,043.60
2024 6 30 1
2024 6 30 2023
– 61 –
2024 6 30
2024 6 30
3.10(2) 3.21
2024 6 30
– 62 –
2,415.67
2024 6 30 1,560.9 64.6%
2024 2024
2024 6 30 6 30
1 1
50% 1,207,835 261,550 40,369 986,654 221,181 2026
40% * 966,268 633,197 12,571 345,642 620,626 2026
10% 241,567 21,300 8,308 228,575 12,992 2026
2,415,670 916,047 61,248 1,560,871 854,799
* 2023
8 29
– 63 –
2021 2
2021 2 2
Gaoling Fund L.P. YHG Investment L.P.
Vivo Opportunity Fund, L.P.
210,508,000
16.33%
14.04% 14.45
421.02 3,041.44 210,508,000
14.45 2021 2 2
15.72
3,041.84 3,041.44 2021 2 10
– 64 –
2024 6 30
2024 2024
1 1 2024 6 30
6 30
(i) 1 ( 1)
2,488 244,463 1
2027
IND
(ii) 23,731 662,180
(iii) 156 273,349
(iv) 53,125 775,406
3,041,440 1,165,542 79,500 1,955,398 1,086,042
1. 2021 2 2
– 65 –
2022 9 21 2,919.07
140.25
2,778.82
2022 9 16
2022 9 16
2024 6 30
2024 2024
1 1 2024 6 30
6 30
1,494,220.6 1,242,867.3 87,134.1 338,487.4 1,155,733.2 2027
116,146.6 25,878.1 3,960.3 94,228.8 21,917.8 2027
273,851.4 159,144.7 16,499.4 131,206.1 142,645.3 2027
60,952.3 32,296.1 3,089.3 31,745.5 29,206.8 2027
833,644.7 364,916.3 167,633.8 636,362.2 197,282.5 2027
2,778,815.6 1,825,102.5 278,316.9 1,232,030.0 1,546,785.6
– 66 –
2024 6 30
6 30
2024 2023
5 419,738 377,549
(60,140) (76,072)
359,598 301,477
5 111,356 131,265
(157,153) (191,208)
(420,822) (358,130)
(91,511) (87,299)
(33,059) (179,150)
(23,663) (23,707)
(668) —
(1,536) (2,087)
(10,465) (20,345)
(267,923) (429,184)
7 (29) —
6 (267,952) (429,184)
(261,840) (422,211)
(6,112) (6,973)
(267,952) (429,184)
9 (0.16) (0.25)
– 67 –
2024 6 30
6 30
2024 2023
6 (267,952) (429,184)
36,331 233,692
36,331 233,692
(231,621) (195,492)
(225,509) (188,519)
(6,112) (6,973)
(231,621) (195,492)
– 68 –
2024 6 30
2024 2023
6 30 12 31
10 805,161 759,764
296,546 293,837
3,125 3,125
36,544 39,007
4,124 5,660
401,016 —
59,033 52,413
1,605,549 1,153,806
118,381 119,095
11 280,677 307,638
12 124,881 113,994
642,941 —
6,903,693 8,224,596
8,070,573 8,765,323
13 117,242 134,905
669,052 667,717
5,000 5,000
11,274 12,008
34,183 23,233
14 1,274,794 1,251,131
2,111,545 2,093,994
5,959,028 6,671,329
7,564,577 7,825,135
– 69 –
2024 2023
6 30 12 31
33,900 26,300
39,781 43,647
15 294,048 305,577
258,369 268,906
626,098 644,430
6,938,479 7,180,705
23 23
(7,386) —
6,919,097 7,147,825
6,911,734 7,147,848
26,745 32,857
6,938,479 7,180,705
– 70 –
2024 6 30
1.
2015 11 3
Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay,
Grand Cayman KY1-9009 Cayman Islands
2020 3 23 2022 9 21
2.
2024 6 30
34
2023 12 31
– 71 –
3.
2023 12
31
16
1
2020
1
2022
7
7
(a) 16 —
—
16
(b) 2020
2022
12
– 72 –
2023 2024 1 1
(c) 7 7
4.
(a)
6 30
2024 2023
418,080 322,234
1,658 55,315
419,738 377,549
– 73 –
(b)
2024 2023
6 30 12 31
1,159,819 1,146,193
36,858 414
1,196,677 1,146,607
10%
6 30
2024 2023
A 187,063 102,863
B 47,426 60,722
C — 55,315
D 37,585 43,363
272,074 262,263
– 74 –
5.
6 30
2024 2023
419,738 377,549
(a)
6 30
2024 2023
417,820 321,466
955 55,315
963 768
419,738 377,549
418,080 322,234
1,658 55,315
419,738 377,549
– 75 –
6 30
2024 2023
418,783 322,234
955 55,315
419,738 377,549
(b)
30
30 90
– 76 –
30
6 30
2024 2023
11,450 29,201
94,559 93,771
603 —
406 8,290
4,338 3
111,356 131,265
– 77 –
6.
6 30
2024 2023
31,031 28,255
14,036 11,870
3,021 2,669
23,663 23,707
(348) 44,918
287,898 251,066
402,493 337,322
60,140 76,072
33,005 178,644
7.
– 78 –
16.5% 2023 16.5%
2,000,000 2023 2,000,000
8.25% 2023 8.25% 16.5% 2023
16.5%
25%
15% 2023 15%
25% 30%
30% 2023
30%
21% 2023 21%
– 79 –
2024 2023 6 30
6 30
2024 2023
29 —
8.
2024 6 30 2023 6
30
9.
6 30
2024 2023
(261,840) (422,211)
– 80 –
6 30
2024 2023
1,688,294 1,684,883
2024 2023 6 30
16
2024 2023 6 30
2024 2023 6 30
10.
2024 6 30 84,030,000 2023
6 30 90,900,000
2024 6 30 35,000
2023 6 30 4,000
– 81 –
11.
2024 2023
6 30 12 31
281,746 276,778
— 31,261
(1,069) (401)
280,677 307,638
2021
2024 2023
6 30 12 31
268,816 248,942
11,861 58,696
280,677 307,638
– 82 –
2024 2023
6 30 12 31
401 132
668 268
— 1
1,069 401
12.
2024 2023
6 30 12 31
64,353 39,044
44,572 62,540
14,633 10,390
1,323 2,020
124,881 113,994
2024 6 30 2023 12 31
– 83 –
13.
2024 2023
6 30 12 31
102,521 124,207
14,686 10,432
16 199
19 67
117,242 134,905
14.
2024 2023
6 30 12 31
1,274,794 1,251,131
2023 1 1 1,197,168
53,963
2023 12 31 1,251,131
23,663
2024 6 30 1,274,794
– 84 –
2018 8
930 6.5%
2024 12 31
2024 8
19
15.
2024 2023
6 30 12 31
1 1 305,577 287,761
14,035 18,969
(25,000) —
(564) (1,153)
294,048 305,577
2021 12 50,000,000
0.35%
2022 6
325,000,000 0.35%
2022 6 2024 2
– 85 –
16.
2023
A 2023 A
A
2015 2016 2018 2020
2023 8 11 2015
2016 2018 2020
A 0.000002 A
B 0.000002 B
2015
2015 2016 9 6
10
183,888,050 B 2015
2015 2023 8 11
2016
2016 2016 9 6
10
22,200,000 B 2016
2016 2023 8 11
– 86 –
2018
2018 2018 11 28
10
68,498,464 B 2018
2018 2023 8 11
2020
2020 2020 7 3
10 2020
10% 10%
2020
2020 2023 8 11
2023 8 31
10 51,481,607
B
– 87 –
2024 2023
1 1 0.1440 23,748 0.1433 29,833
0.1780 2,790 0.1780 1,110
0.1780 (4,240) 0.1780 (430)
— — 0.1591 (8,018)
6 30 0.1418 22,298 0.1387 22,495
2023 6 30
1.0472
2024 6 30
2,650 0.000002 2020 12 25 2029 8 1
1,450 0.055 2023 9 16 2031 9 15
18,198 0.178 2022 9 16 2034 6 27
22,298
– 88 –
2023 6 30
2,770 0.000002 2018 9 6 2029 8 1
1,900 0.055 2022 3 16 2031 9 15
17,825 0.178 2020 8 2 2033 3 30
22,495
6 30
2024 2023
(%) 62.17 66.04
(%) 4.26–4.96 3.64–4.53
10 10
H 0.62 1.07
2024 6 30 10.22
2023 6 30 43.1
A
A 2023 6 2 2023 6 2
72
A 8,948,750
0.51% A
– 89 –
2024 A 1.29 2.46
2023 5.49 6.53 2024 6 30
9.87 2023 6 30
1.8
Black-Scholes
6 30
2024 2023
(%) 32.48–35.18 30.63–35.68
(%) 1.66–2.01 1.97–2.33
2–5 2–5
A 7.44 12.28
A
2024 2023
1 1 6.95 7,090 — —
6.95 1,737 6.95 7,209
6.95 183 —
6 30 6.95 8,644 6.95 7,209
– 90 –
2024 6 30
8,644 6.95 2024 6 2 2029 5 30
17.
2024 2023
6 30 12 31
43,588 46,980
18.
(a)
6 30
2024 2023
11,969 12,366
105 69
(22,215) 19,686
(10,141) 32,121
– 91 –
(b)
*
* 2023 7 14
(c)
6 30
2024 2023
(i) 54 —
(i) — 485
54 485
(ii) 53 78
(i)
– 92 –
(ii)
(iii) 2016 1 4 2018 8 8
2018 2016 1
4 2020 7 10
2020
2018 2020
2020
(d)
2024 2023
6 30 12 31
54 3
54 3
19.
2023 6 2 A
2024 6 2024 7 11
1,634,750
2024 7
794 300 794
2024 7
1,280,740,000 2024 8
– 93 –
(www.hkexnews.hk) (www.innocarepharma.com)
D2 2024 6 30
19DEL 19
AD
ALL
AML
AQP4 IgG 4
ARR
ArriVent ArriVent Biopharma
ASH
B B BCR T
B
– 94 –
Biogen Biogen Inc. BIIB
BTD
BTK BTK
CD20 B CD20 MS4A1
B
CDC
CDE NMPA
C1
CLL
CNSL
9969
2015 11 3
2020 3 23
2022 9 21
– 95 –
DLBCL B
DLT
EGFR
EULAR
FGFR
FL
GMP
2019 9
IBD
– 96 –
ICP-105
ICP-192
ICP-022
IL-2 -2
IL-12 -12
IL-17 -17
IL-23 -23
IMiD
IND
IRC
ITK T
ITP
JAK
2020 3 23
MCD B (DLBCL)
MYD88L265P CD79B MCD
– 97 –
MCL B
MOA
C3
MS
MZL
NDA
BLA
NMOSD
NMPA
NRDL
NSCLC
NTRK
FGFR (FGFR)
TRK
PD
– 98 –
PK
2020 3 11
R/R r/r
R-CHOP
RICE
264,648,217
2022 9 21
SC
0.000002
SHP2 RAS
SLE
– 99 –
SLL
SRI SLE
T
T
T B
NK
TDCC T
TRK
TYK2 2
UC
FDA FDA
Vivo Vivo Opportunity Fund, L.P Vivo Capital VIII,
LLC
WM
– 100 –
2024 8 20
– 101 –